Search results
White blood cell “nets” could be early warning | Newswise
Newswise· 6 days agoThe findings, out now in Blood Advances, show that a process called NETosis, in which neutrophils eject their DNA to create webs, may contribute to the development of cytokine release syndrome ...
ASCO24: Tagrisso in the spotlight, Caribou’s adjustment and Lilly’s KRAS competitor
BioPharma Dive via Yahoo Finance· 6 days agoAstraZeneca’s therapy could see wider use after ASCO data. Elsewhere, Caribou sought to explain an...
BlueSphere Bio's huge week with FDA approval for dosing and National Cancer Institute agreement -...
The Business Journals· 2 days agoBlueSphere Bio, a UPMC Enterprises spinout and Pittsburgh-based drug development company, logged a big week in its development with a clearance from the U.S. Food and Drug Administration and ...
MVP & Big E Undergo Stem Cell Treatment In Cancun
Wrestle Zone via Yahoo News· 5 days agoAfter landing down in Cancun on June 2, MVP provided a glimpse into his therapy, which […] The post MVP & Big E Undergo Stem Cell Treatment In Cancun...
Most stem cells die after being injected into the brain. This new technique could change that
UB Reporter· 4 days agoMultiple sclerosis (MS) is the most common demyelinating disease, affecting more than 2.5 million individuals globally every year. Stem cell therapy to ...
How tumor stiffness alters immune cell behavior to escape destruction
Medical Xpress· 4 days agoResearchers presume that part of the reason why these therapies fail is due to tumor-associated...
MVP & Big E Undergo Stem Cell Treatment In Cancun
Wrestle Zone· 5 days agoMVP and Big E are focused on their health and wellness. Two weeks ago, MVP revealed his plans to undergo stem cell treatment in Cancun, Mexico, with the...
Is Geron Stock a Buy Following Its First New Drug Approval?
Motley Fool via Yahoo Finance· 21 hours agoExpectations for Rytelo aren't entirely baked into Geron's stock price yet. Biotech stocks tend to...
ASCO: Cautious Big Pharmas double down on past wins—steering clear of radioligands and cell therapy
FierceBiotech· 4 days agoThis year’s American Society of Clinical Oncology (ASCO) conference in Chicago marked a return to...
CARVYKTI® (ciltacabtagene autoleucel) significantly improved progression-free survival and deepened...
Valley City Times Record· 5 days agoJohnson & Johnson announced today results from a subgroup analysis of the Phase 3 CARTITUDE-4 study. Data from the CARTITUDE-4 study supported the recent U.S. FDA approval of CARVYKTI®, the ...